US biotechnology company Novavax Inc (Nasdaq:NVAX) announced on Wednesday that the US Food and Drug Administration (FDA) has approved the Nuvaxovid 2025-2026 Formula for the prevention of COVID-19.
The formula was approved for adults aged 65 years and older, or individuals from 12 years with at least one underlying condition that puts them at high risk of severe outcomes from COVID-19.
Clinical and preclinical data have previously shown that Nuvaxovid is safe and effective for the prevention of COVID-19, and induces immunity across currently circulating JN.1 lineage strains, including NB.1.8.1, LP.8.1, XFG, XFC, LF.7 and XEC.
According to Novavax, Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the United States for the 2025-2026 vaccination season.
Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
GC Biopharma granted CMO rights for Curevo Vaccine's shingles vaccine
TransCode acquires Polynoma and secures USD25m investment from CK Life Sciences
Wasatch BioLabs adds three Oxford Nanopore-developed research-use-only assays to service portfolio
GSK and IQVIA expand vaccine track with local data to drive targeted public health action
AstraZeneca launches online platform to expand patient access to medications
Sanofi increases Sanofi Ventures funding by USD625m to boost biotech and digital health investments
GC Biopharma submits IND application in South Korea for Phase 1 trial of COVID-19 vaccine candidate
AusperBio completes patient enrolment in two Phase II clinical trials of AHB-137
LakeShore Biopharma receives Nasdaq delisting determination letter